<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04525794</url>
  </required_header>
  <id_info>
    <org_study_id>C1904</org_study_id>
    <nct_id>NCT04525794</nct_id>
  </id_info>
  <brief_title>BRight DCB First-in-Human Study</brief_title>
  <official_title>BIOTRONIK- First-in-Human Assessment of the Safety and Clinical Performance of a Sirolimus Derivative-Coated Balloon (BRight DCB) in the Treatment of Subjects With de Novo Lesions in the Superficial Femoral and Proximal Popliteal Artery (BRight First Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik CRC Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biotronik CRC Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this clinical study is to assess the safety and clinical performance of&#xD;
      the BRight drug-coated balloon (DCB) in the treatment of lower limb arteries stenosis in&#xD;
      subjects with Peripheral Artery Disease (PAD).&#xD;
&#xD;
      The primary endpoint will be Late Lumen Loss (LLL) of the target lesion at 6 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Late Lumen Loss</measure>
    <time_frame>6 months post index procedure</time_frame>
    <description>Late Lumen Loss, as measure by quantitative vascular angiography (QVA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>during procedure</time_frame>
    <description>Successful delivery, balloon inflation/deflation and retrieval of the intact trial device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute technical success</measure>
    <time_frame>during procedure</time_frame>
    <description>Successful vascular access and completion of the endovascular procedure and immediate achievement of a final residual diameter stenosis of ≤30% of the treated lesion by core laboratory assessed QVA on the completion angiography with no bailout stenting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute procedural success</measure>
    <time_frame>72 hours post index procedure</time_frame>
    <description>Technical success without the occurrence of death, major target limb amputation, thrombosis of the target lesion, or clinically-driven TLR within 72 hours of the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE) rate</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>MAE is a composite of device or procedure related death within 30 days post index procedure, major index limb amputation, cd TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Lesion Revascularization (cd TLR) rate</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>cd TLR is defined as any repeat intervention of the target lesions or surgical bypass of the target vessel performed for restenosis &gt; 50% or other complication involving the target lesion, after documentation of recurrent clinical symptoms of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (cd TVR) rate</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>cd TVR, defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel, after documentation of recurrent clinical symptoms of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause of death rate</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation (minor and major) rate</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>rate of amputation (minor and major)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Classification as compared to baseline</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>change in the Rutherford classification between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in resting target limb Ankle Brachial Index (ABI) as compared to baseline</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>change in ABI between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion Binary Restenosis</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>Defined as duplex ultrasound peak systolic velocity ratio (PSVR) &gt; 2.5 (if DUS is completed) or angiographic assessment which suggests stenosis &gt; 50% by QVA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion primary patency</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>Target lesion primary patency defined as duplex ultrasound peak systolic velocity ratio (PSVR) ≤ 2.5 (if DUS is completed) or angiographic assessment which suggests stenosis ≤ 50% by QVA and the absence of Clinically-driven TLR (adjudicated by a CEC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Walking Impairment questionnaire (WIQ) as compared to baseline</measure>
    <time_frame>1, 6 and 12 months post index procedure</time_frame>
    <description>change in WIQ between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embolic event of the index limb</measure>
    <time_frame>during procedure, 1, 6 and 12 months post index procedure</time_frame>
    <description>occurrence of embolic event as visualized on angiography</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>BRight DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BRight DCB</intervention_name>
    <description>The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.</description>
    <arm_group_label>BRight DCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject has provided written informed consent&#xD;
&#xD;
          2. The subject is willing to participate in the clinical investigation and to comply with&#xD;
             the study procedures and follow-up visits&#xD;
&#xD;
          3. Lifestyle-limiting claudication or rest pain requiring treatment of superficial&#xD;
             femoral (SFA) and/or proximal popliteal artery (PPA)&#xD;
&#xD;
          4. Rutherford-Becker Clinical Category of 2, 3 or 4&#xD;
&#xD;
          5. Target vessel reference diameter ≥5 mm and ≤ 6 mm (by visual estimation)&#xD;
&#xD;
          6. De novo lesion with &gt;50% stenosis by operator visual estimate within the SFA and/or&#xD;
             proximal popliteal arteries in a single limb.&#xD;
&#xD;
          7. Lesion must be located ≥ 1 cm below the Common Femoral Artery (CFA) bifurcation and&#xD;
             terminate distally at ≥ 3 cm proximal to the knee joint (radiographic joint space)&#xD;
&#xD;
          8. Single lesion length ≤100 mm for de novo stenotic lesions, or ≤ 70 mm for occluded&#xD;
             lesions (one long lesion or multiple serial lesions) by operator visual estimate.&#xD;
             Note: Only 1 lesion per patient can be treated. Multiple serial lesions are allowed&#xD;
             provided that they can be treated as a single lesion with one balloon.&#xD;
&#xD;
          9. Successful guidewire crossing of lesion.&#xD;
&#xD;
         10. After pre-dilatation, the target lesion is ≤ 30% residual stenosis with no flow&#xD;
             limiting dissection and treatable with a single balloon&#xD;
&#xD;
         11. Inflow artery is patent, free from significant lesion stenosis (&gt;50% stenosis&#xD;
             considered significant) as confirmed by angiography.&#xD;
&#xD;
         12. Target limb with at least 1 patent (less than 50% stenosis) tibio-peroneal run-off&#xD;
             vessel in the target limb confirmed at baseline. (Note: treatment of outflow disease&#xD;
             is not permitted.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant, lactating, or intended to become pregnant, or males&#xD;
             intending to father children during the study&#xD;
&#xD;
          2. Subject under current medication known to affect CYP3A4 metabolism&#xD;
&#xD;
          3. Contraindication to dual anti-platelet therapy&#xD;
&#xD;
          4. Subject is receiving chronic anticoagulation therapy (e.g. low molecular weight&#xD;
             heparin, warfarin, or novel direct oral anticoagulants (N(D)OACs)).&#xD;
&#xD;
          5. Known intolerance to study medications, Limus- like drug or contrast agents that in&#xD;
             the opinion of the investigator could not be adequately pretreated&#xD;
&#xD;
          6. Current participation in an investigational drug or another device study&#xD;
&#xD;
          7. History of hemorrhagic stroke within 3 months&#xD;
&#xD;
          8. Patients with a history of Myocardial Infarction (MI) or thrombolysis within 30 days&#xD;
             prior-index procedure&#xD;
&#xD;
          9. Previous or planned surgical or interventional procedure within 14 days before or 30&#xD;
             days after index procedure (successful treatment of the ipsilateral and contralateral&#xD;
             iliac arteries is permitted prior to enrollment- contralateral iliac artery treatment&#xD;
             with no drug eluting technology is allowed during the index procedure)&#xD;
&#xD;
         10. Prior endovascular treatment of the target lesion (e.g., POBA, DCB, BMS, DES, cutting&#xD;
             balloons, scoring balloons, cryoplasty, thrombectomy, atherectomy, brachytherapy or&#xD;
             laser devices)&#xD;
&#xD;
         11. Previous placement of a bypass graft proximal to the target lesion&#xD;
&#xD;
         12. Chronic renal insufficiency (eGFR &lt; 30 mL/min within 72 hours prior to index&#xD;
             procedure)&#xD;
&#xD;
         13. No normal proximal arterial segment in which duplex ultrasound velocity ratios could&#xD;
             be measured.&#xD;
&#xD;
         14. Subject is unable to walk without assistance (e.g. walker, cane).&#xD;
&#xD;
         15. Subject is receiving immunosuppressant therapy.&#xD;
&#xD;
         16. Subject has known or suspected active infection at the time of the index procedure.&#xD;
&#xD;
         17. Subject has platelet count &lt; 100,000/mm3 or &gt; 700,000/mm3.&#xD;
&#xD;
         18. Subject has white blood cell (WBC) count &lt; 3,000/mm3.&#xD;
&#xD;
         19. Subject is unable to tolerate blood transfusions because of religious beliefs or other&#xD;
             reasons.&#xD;
&#xD;
         20. Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3&#xD;
             months prior to the index procedure.&#xD;
&#xD;
         21. Life expectancy less than 12 months due to other comorbidities, that in the&#xD;
             investigators opinion, could limit subject ability to comply with the study required&#xD;
             follow-up visits/procedure and threaten the study scientific integrity&#xD;
&#xD;
         22. Treatment of the contralateral limb during the same procedure or within 30 days&#xD;
             following the study procedure (exclusive of the iliac arteries, which can be treated&#xD;
             prior to enrollment or during the index procedure if no drug eluting technology is&#xD;
             used)&#xD;
&#xD;
         23. Non femoral vascular access&#xD;
&#xD;
         24. Target lesion would require treatment with more than one balloon&#xD;
&#xD;
         25. Known inadequate distal outflow&#xD;
&#xD;
         26. Acute or sub-acute thrombus in the target vessel&#xD;
&#xD;
         27. Aneurysmal target vessel&#xD;
&#xD;
         28. Use of adjunctive therapies (i.e. laser, atherectomy, cryoplasty, scoring/cutting&#xD;
             balloon, brachytherapy) during the study procedure in the target lesion or target&#xD;
             vessel&#xD;
&#xD;
         29. Presence of concentric calcification that precludes PTA pre-dilatation&#xD;
&#xD;
         30. Significant contralateral or ipsilateral common femoral disease that requires&#xD;
             intervention during the index procedure&#xD;
&#xD;
         31. Persistent hemodynamically-significant stenosis following predilatation or residual&#xD;
             stenosis of &gt;30%, stent placement, or flow-limiting (Grade D or greater) dissection&#xD;
             following pre-dilatation&#xD;
&#xD;
         32. In-stent restenosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>HELENE KUISSU</last_name>
    <phone>+41 44 864 53 68</phone>
    <email>helene.kuissu@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carsten Ritter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrice Mwipatayi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vikram Puttaswamy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Holden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

